Geron (GERN) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending the approval of Rytelo for the treatment of adult patients with transfusion-dependent anemia due to very low, low or intermediate risk myelodysplastic syndromes without an isolated deletion 5q cytogenetic abnormality and who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy. The European Commission, which has the authority to approve medicines in the European Union, will review the CHMP’s recommendation and is expected to make a final decision on the marketing authorization application in the following months.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GERN:
- Geron announces result from IMproveMF study at ASH
- Geron Q4 revenue estimate raised above consensus at Barclays
- Geron Corporation’s Q3 2024: Strong RYTELO Launch and Financial Growth
- Geron price target raised to $9 from $8 at H.C. Wainwright
- Geron announces $375M in synthetic royalty, debt financings with Royalty Pharma